ARTICLE | Emerging Company Profile
Genomic-linked outcomes
How 14M Genomics will link cancer genome profiling to clinical outcomes
March 16, 2015 7:00 AM UTC
14M Genomics Ltd. aims to improve the prognostic value of cancer genome profiling by linking a patient's genomic signature with clinical outcomes compiled from large data sets.
14MG's tests use next-generation sequencing combined with algorithms to map a patient's cancer genome and identify mutations. The results of the test are intended to inform doctors which genetic mutations are driving a patient's cancer and which therapy will provide the best outcome based on a correlation between the genomic signature and clinical data. ...